Diplomat Pharmacy (DPLO) Announces Quarterly Earnings Results

Diplomat Pharmacy (NYSE:DPLO) released its quarterly earnings data on Friday. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.10), MarketWatch Earnings reports. Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. The company had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the prior year, the company earned $0.09 earnings per share. The business’s revenue was up 17.8% compared to the same quarter last year. Diplomat Pharmacy updated its FY 2019 guidance to $-0.5-0.34 EPS and its FY19 guidance to ($0.50-0.34) EPS.

Shares of NYSE:DPLO traded down $0.37 during midday trading on Friday, reaching $6.05. The company’s stock had a trading volume of 21,414 shares, compared to its average volume of 1,368,443. Diplomat Pharmacy has a fifty-two week low of $5.56 and a fifty-two week high of $28.74. The firm has a market cap of $485.54 million, a PE ratio of 7.40 and a beta of 0.74. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.66 and a current ratio of 0.95.

DPLO has been the subject of several recent analyst reports. TheStreet lowered Diplomat Pharmacy from a “c-” rating to a “d+” rating in a research note on Monday, March 4th. Morgan Stanley lowered their target price on Diplomat Pharmacy from $20.00 to $18.00 and set an “equal weight” rating for the company in a research note on Monday, December 3rd. Zacks Investment Research upgraded Diplomat Pharmacy from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 11th. Mizuho set a $8.00 target price on Diplomat Pharmacy and gave the company a “hold” rating in a research note on Friday, February 22nd. Finally, Lake Street Capital lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating and lowered their target price for the company from $30.00 to $15.00 in a research note on Tuesday, January 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $13.78.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc boosted its holdings in Diplomat Pharmacy by 4.0% in the third quarter. Vanguard Group Inc now owns 5,461,715 shares of the company’s stock valued at $106,011,000 after acquiring an additional 209,939 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Diplomat Pharmacy by 7.8% during the 3rd quarter. Wells Fargo & Company MN now owns 95,621 shares of the company’s stock valued at $1,856,000 after purchasing an additional 6,898 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Diplomat Pharmacy by 21.8% during the 4th quarter. Rhumbline Advisers now owns 161,436 shares of the company’s stock valued at $2,173,000 after purchasing an additional 28,901 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Diplomat Pharmacy by 6.3% during the 4th quarter. Arizona State Retirement System now owns 87,165 shares of the company’s stock valued at $1,173,000 after purchasing an additional 5,133 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Diplomat Pharmacy during the 3rd quarter valued at about $696,000. Institutional investors own 86.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2019/03/15/diplomat-pharmacy-dplo-announces-quarterly-earnings-results.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: Why is the Consumer Price Index (CPI) important?

Earnings History for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.